Table 2. Comparison of clinical and echocardiographic characteristics between patients without and with LVH.
| Characteristics | Non-LVH (n = 302) | LVH (n = 382) |
| ABI | ||
| ≥0.9 to<1.3 | 87.7 | 78.2* |
| <0.9 in either leg | 7.3 | 9.9 |
| ≥1.3 in either leg | 5.0 | 11.9* |
| Age (year) | 63.8±12.2 | 66.3±12.6* |
| Male gender (%) | 69.1 | 53.7** |
| Smoking history (%) | 37.5 | 30.5 |
| Diabetes mellitus (%) | 39.1 | 39.7 |
| Hypertension (%) | 75.9 | 79.5 |
| Coronary artery disease (%) | 17.4 | 17.8 |
| Cerebrovascular disease (%) | 12.1 | 9.7 |
| Stage of CKD | ||
| Stage 3 (%) | 74.1 | 72.4 |
| Stage 4 (%) | 16.8 | 12.1 |
| Stage 5 (%) | 9.1 | 15.5* |
| Systolic blood pressure (mmHg) | 136.2±19.7 | 143.0±22.7** |
| Diastolic blood pressure (mmHg) | 78.1±11.5 | 78.6±13.3 |
| Pulse pressure (mmHg) | 58.1±13.7 | 64.4±15.6** |
| Body mass index (kg/m2) | 25.0±3.8 | 26.0±4.2* |
| Laboratory parameters | ||
| Albumin (g/dL) | 4.19±0.34 | 4.03±0.45** |
| Fasting glucose (mg/dL) | 120.0±50.3 | 115.2±41.1 |
| Triglyceride (mg/dL) | 118.5 (88–189.5) | 132 (88–182) |
| Total cholesterol (mg/dL) | 188.5±38.7 | 189.9±41.4 |
| Hematocrit (%) | 39.1±5.9 | 37.4±6.2* |
| eGFR (mL/min/1.73 m2) | 41.4±16.0 | 38.6±16.8* |
| Uric acid (mg/dL) | 7.4±2.1 | 7.5±2.1 |
| Proteinuria (%) | 50.8 | 64.6* |
| Medications | ||
| Aspirin use (%) | 17.0 | 21.0 |
| ACEI and/or ARB use (%) | 62.8 | 62.2 |
| Non-ACEI/ARB antihypertensive drug use (%) | 66.8 | 76.9* |
| Statin use (%) | 20.8 | 22.4 |
| Echocardiographic data | ||
| LVMI (g/m2) | 89.2±18.2 | 155.1±43.1** |
| LVEF (%) | 65.8±11.6 | 60.4±14.7** |
| E-wave deceleration time (ms) | 214.7±64.4 | 213.0±72.3 |
| E/A | 0.95±0.57 | 0.96±0.51 |
*
P<0.05, ** P<0.001 compared with patients without LVH. Abbreviations are the same as in Table 1.